http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4815448-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_09016bca9ce1fc8f05acf0ac4cfb2885
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N2005-1098
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2121-00
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K41-0085
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K41-00
filingDate 1986-04-07-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 1989-03-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e4dffa27121d3101ec839ceb391c0a2d
publicationDate 1989-03-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber US-4815448-A
titleOfInvention Mossbauer cancer therapy
abstract Frequency selective radiation therapy providing selective tissue damage or necrosis by irradiating a component element of the target tissue at the corresponding Mossbauer absorption frequency. The component radiation absorption at the Mossbauer absorption frequency is thus enhanced many times over the absorption of the surrounding tissue having a different Mossbauer absorption frequency. The energy thusly absorbed by the target tissue component is converted to and remitted as Auger electrons, which provide intranuclear radiation resulting in lethal double strand breaks in the DNA molecules of the target tissue. The therapy is administered in frequency and tissue selective modes of treatment, and may be combined with conventional chemotherapeutic agents to provide a further enhanced treatment modality. Moreover, the source frequency can be adjusted to enhance the killing effect. The therapy method and apparatus according to the present invention is useful in combination with naturally occurring or administered pharmaceutical stable isotope absorbers, having significantly reduced side effects by comparison to conventional chemotherapy or radiation therapy.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011040295-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9035237-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6780149-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8210899-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2013096362-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005021049-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2005281374-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5391139-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0059575-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6685619-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7446328-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2007164230-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7696499-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6454695-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011218679-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7354433-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7199382-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8569720-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8184773-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7346144-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8790381-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010192303-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7280633-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7173265-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9084886-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8093569-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5782739-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8418288-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5354864-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5044006-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8981324-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010067659-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8269195-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7949096-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2008208294-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2004236267-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2006002511-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/DE-4325724-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2006017022-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8523630-B2
priorityDate 1985-03-19-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4541438-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4361544-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-3794840-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4516535-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-3631247-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-3257558-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-8501871-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394280
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID229464183
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128090136
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID53887896
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID229464181
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID57417070
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID56629756

Total number of triples: 73.